The ICRAKI trial compared intermittent hemodialysis with continuous renal-replacement therapy as initial treatment for acute kidney injury in critically ill adults. Research findings are summarized in a new Quick Take video. https://t.co/uR7BLXJyDP
#KidneyWk 2026 Round Up: Four articles were simultaneously published in NEJM and presented at this year’s American Society of Nephrology Meeting (@ASNKidney) in Denver.
We are not slowing down. 🚀
Our Artemis III mission will send four astronauts to low Earth orbit next year to test critical systems needed for future lunar landings https://t.co/G5CkHbQhFR and we’re accelerating efforts to ensure the success of Artemis IV, the first Artemis mission on the lunar surface https://t.co/zEDKEcLpXY.
Presented at #KidneyWk:
In a phase 3, double-blind, randomized trial involving patients with IgA nephropathy, sibeprenlimab stabilized the eGFR slope over 24 months, consistent with a reduced risk of kidney-function decline. Full VISIONARY trial results: https://t.co/T8euA518cz
@ASNKidney